Immunology
Immune System Overview & Classification
- Adaptive Immune System Components: ((IMM001)): Composed of T lymphocytes (cell-mediated immunity, MHC recognition, cytokine production) and B lymphocytes (humoral immunity, antigen-specific antibody production via plasma cells). Hallmark features are antigen specificity, immunologic memory, and clonal expansion/contraction.
Primary Antibody & B-Cell Deficiencies
- X-Linked Agammaglobulinemia (XLA / Bruton Agammaglobulinemia): ((((IMM021)) · ((IMM023)))): Caused by mutations in the **BTK gene, resulting in maturation arrest at the pre-B-cell stage. Presents after 6 months of age** (when maternal IgG wanes) with recurrent pyogenic infections (pneumonia, otitis, meningitis) and atrophied tonsils and lymph nodes. Flow cytometry shows absent CD19+ B cells with normal T-cell numbers and severely decreased serum immunoglobulins (IgG, IgA, IgM).
- Common Variable Immunodeficiency & Selective IgA Deficiency: ((((IMM007)) · ((IMM009)) · ((IMM025)))): Selective IgA deficiency is the most common primary immunodeficiency, defined by serum IgA <5–10 mg/dL with normal IgG/IgM and normal T cells, diagnosed only after 4 years of age. Features include sinopulmonary infections, Giardia lamblia diarrhea, celiac association, and risk of anaphylaxis from plasma-containing blood products (due to anti-IgA antibodies).
- X-Linked Hyper-IgM Syndrome: ((((IMM024)) · ((IMM026)))): Caused by mutations in the **CD40LG gene** (CD40L/CD154 deficiency on activated CD4+ T cells), leading to a defect in class switch recombination and somatic hypermutation. Characterized by markedly elevated IgM with low/absent IgG, IgA, and IgE, and susceptibility to pyogenic and opportunistic infections.
Cellular, Combined & Phagocytic Deficiencies
- DiGeorge Syndrome (22q11.2 Deletion): ((((IMM003)) · ((IMM005)) · ((IMM008)))): Caused by microdeletion of chromosome 22q11.2 disrupting the third and fourth pharyngeal pouches. Classic triad/findings include conotruncal cardiac anomalies (Tetralogy of Fallot, truncus arteriosus), hypocalcemia/neonatal seizures (parathyroid hypoplasia), and thymic hypoplasia leading to T-cell deficiency. Note: Cleft palate is seen, but cleft lip is not a feature.
- Wiskott-Aldrich Syndrome (WAS): ((((IMM002)) · ((IMM022)))): Caused by mutations in the **WAS gene** (defective actin cytoskeleton). Characterized by the WATER mnemonic: Wiskott-Aldrich, Atopic dermatitis (eczema), Thrombocytopenia with small platelets (low MPV), Elevated IgE/IgA, and Recurrent infections. Major non-infectious, non-bleeding cause of death is EBV-associated B-cell malignancies.
- Leukocyte Adhesion Deficiency (LAD-1 & LAD-3): ((((IMM011)) · ((IMM012)) · ((IMM013)) · ((IMM027)) · ((IMM028)))): Autosomal recessive disorders of neutrophil migration. LAD-1 (ITGB2/CD18 defect) presents with delayed umbilical cord separation (>3 weeks), marked leukocytosis (WBC >50,000/mm³), and recurrent bacterial infections without pus formation. LAD-3 (FERMT3/Kindlin-3 defect) uniquely combines leukocyte adhesion failure with defective platelet aggregation and bleeding tendencies (resembling Glanzmann thrombasthenia).
- Chediak-Higashi Syndrome: ((((IMM014)) · ((IMM015)) · ((IMM029)))): Autosomal recessive mutations in the **LYST gene** (chromosome 1q2-q44) causing abnormal lysosomal trafficking and giant granules. Features include partial oculocutaneous albinism (silvery hair, light skin), neutrophil dysfunction (recurrent staphylococcal infections), prolonged bleeding time with normal platelets, progressive peripheral neuropathy, and risk of a fatal HLH-like accelerated phase. Management mainstay is early allogeneic HSCT (which corrects hematologic/immune defects but may not halt neurodegeneration).
- Myeloperoxidase (MPO) Deficiency: ((IMM016)): Relatively common defect in neutrophil oxidative killing. Most individuals are asymptomatic due to compensatory mechanisms and MPO deficiency is typically detected incidentally on neutrophil function testing (e.g., NBT/DHR).
- Chronic Granulomatous Disease (CGD) & Vaccine Safety: ((IMM030)): Defect in NADPH oxidase causing impaired intracellular killing of catalase-positive organisms (S. aureus, Serratia, Aspergillus). Adaptive immunity is intact, allowing most viral vaccines, but live BCG vaccine is absolutely contraindicated.
Complement Deficiencies
- Terminal Complement vs. Early Classical Pathways: ((((IMM034)) · ((IMM035)))): Recurrent Neisseria meningitidis infections with normal immunoglobulins/neutrophils indicate a terminal complement pathway defect (C5-C9), evaluated by CH50 assay. Conversely, early classical pathway deficiencies (C1q, C2, C4)—especially C1q—strongly predispose to an SLE-like autoimmune syndrome (malar rash, photosensitivity, positive ANA) due to impaired immune complex clearance.
Hematopoietic Stem Cell Transplantation (HSCT) Complications
- Infectious Phases Post-HSCT: ((IMM019)): Early (<30 days): Dominated by neutropenia-associated bacterial and Candida infections. Intermediate (30–100 days): CMV, opportunistic viruses, and invasive molds (e.g., Aspergillus). Late (>100 days): Chronic GVHD and encapsulated organisms.
- Veno-Occlusive Disease (VOD) / Sinusoidal Obstructive Syndrome: ((IMM017)): Early complication (≤30 days post-transplant) featuring tender hepatomegaly, right upper quadrant pain, rapid weight gain/ascites, and hyperbilirubinemia. Severity is graded via bilirubin, weight gain, renal, and respiratory status.
- Graft Failure & PTLD: ((((IMM018)) · ((IMM020)))): Primary graft failure is defined as failure to achieve an ANC ≥0.5 × 10⁹/L by day +28 with donor engraftment failure. EBV-associated PTLD presents early (1–6 months) after T-cell depleted transplants; first-line therapy includes reduction of immunosuppression and rituximab.
- Transplant-Related Pulmonary & Inflammatory Complications: ((((IMM031)) · ((IMM033)))): Bronchiolitis obliterans is a pulmonary manifestation of chronic GVHD (associated with sicca/scleroderma), managed with systemic immunosuppression and inhaled therapies. Immune Reconstitution Inflammatory Syndrome (IRIS) causes paradoxical worsening of inflammatory symptoms (e.g., lymphadenopathy) during immune recovery despite effective antimicrobial therapy.
Complement and Angioedema Disorders
- Hereditary Angioedema Type I: ((IMM036)): Autosomal dominant disorder caused by quantitative deficiency of C1 esterase inhibitor (C1-INH), accounting for ~85% of HAE cases; characterized by recurrent, non-pruritic angioedema of the face, extremities, larynx, or GI tract triggered by minor trauma. Diagnostic hallmarks include low serum C4 and decreased C1-INH antigenic level and function due to uncontrolled bradykinin production. - Distinguishing features: Allergic angioedema always presents with urticaria, itching, and responds to epinephrine/antihistamines; HAE is completely unresponsive to epinephrine, antihistamines, or corticosteroids. ACE-inhibitor–induced angioedema also involves bradykinin buildup but lacks a familial history and complement abnormalities.
- (A) T and B lymphocytes
- (B) Acute-phase proteins
- (C) Cytokines
- (D) Complements
💡 Click to Reveal Answer & Nelson Rationale
The adaptive immune system is composed of T lymphocytes and B lymphocytes and their effector molecules.These cells mediate antigen-specific responses and are capable of immunologic memory, allowing a more rapid and effective response upon re-exposure to the same pathogen. T lymphocytes: Responsible for cell-mediated immunity. They recognize antigen fragments presented by MHC molecules and coordinate immune responses via cytokine production or cytotoxicity. B lymphocytes: Mediate humoral immunity through the production of antigen-specific antibodies after activation and differentiation into plasma cells. **Key feature of adaptive immunity:** Antigen specificity, Immunologic memory, Clonal expansion and contraction after antigen exposure **Mnemonic:** Adaptive = "A" for Antigen-specific + memory (T & B cells)
- (A) Graft-versus-host disease
- (B) Protracted bloody diarrhea
- (C) EBV-associated malignancies
- (D) Development of autoimmune disease
💡 Click to Reveal Answer & Nelson Rationale
Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive primary immunodeficiency disorder caused by mutations in the WAS gene on the X chromosome, leading to a defective WASP (Wiskott–Aldrich Syndrome Protein). This protein is crucial for actin cytoskeleton remodeling, which affects immune cell signaling, migration, and function. As a result, patients develop a combined immunodeficiency (defective T cells, B cells, and NK cells) with impaired immune surveillance, predisposing them to malignancy, particularly those associated with Epstein–Barr virus (EBV). EBV-associated B-cell lymphomas and lymphoproliferative disorders are the most frequent malignancies in WAS and represent a major cause of death after infections and bleeding.EBV drives uncontrolled B-cell proliferation in the setting of defective cytotoxic T-cell control. **Mechanism of predisposition to malignancy:** Defective cytotoxic T-cell and NK-cell function → failure to eliminate EBV-infected cells, Impaired apoptosis and immune regulation → uncontrolled proliferation of abnormal B cells, Chronic immune activation and cytokine imbalance → genomic instability **Major causes of mortality in WAS:** Severe infections (due to combined immunodeficiency), Bleeding complications (due to microthrombocytopenia), EBV-associated B-cell lymphomas, Autoimmune complications (secondary) **Management and Prognosis:** Hematopoietic stem cell transplantation (HSCT) is curative if performed early.Without HSCT, most patients succumb to infection, bleeding, or EBV-driven malignancy by adolescence or early adulthood.
- (A) Microdeletions of chromosome 22q11.2
- (B) Interstitial deletion of the long arm of chromosome 15 (15q11–13)
- (C) Presence of two copies of paternally derived chromosome 11p15.5
- (D) Presence of mutated gene on long arm of chromosome 11 (11q22–23)
💡 Click to Reveal Answer & Nelson Rationale
The child’s presentation — hypocalcemic seizures, recurrent infections, cardiac defects (holosystolic murmur suggesting conotruncal anomaly), and craniofacial anomalies (cleft palate) — is characteristic of DiGeorge syndrome (22q11.2 deletion syndrome). **Pathophysiology:** Chromosome 22q11.2 microdeletion disrupts embryologic development of the third and fourth pharyngeal pouches. This leads to hypoplasia or aplasia of the thymus and parathyroid glands. The resultant findings include: T-cell immunodeficiency → recurrent infections (especially viral and fungal). Hypocalcemia due to parathyroid hypoplasia → neonatal seizures. Congenital heart defects, especially conotruncal anomalies (e.g., truncus arteriosus, interrupted aortic arch, VSD). Craniofacial anomalies: cleft palate, short philtrum, hypertelorism, mandibular hypoplasia, posteriorly rotated ears. **Mnemonic: **“CATCH-22”, Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia, 22q11.2 deletion **Immunologic defect:** Decreased T-cell number and function. B-cell numbers are normal, but antibody response to new antigens is impaired due to lack of T-cell help. **Genetic confirmation:** Detected by fluorescence in situ hybridization (FISH) or chromosomal microarray showing 22q11.2 deletion.
- (A) Autosomal recessive inheritance
- (B) STAT3 deficiency
- (C) Staphylococcal infections are most common
- (D) Exceptionally high serum IgE concentration
💡 Click to Reveal Answer & Nelson Rationale
Job syndrome, also known as Hyper-IgE syndrome, is classically inherited in an autosomal dominant pattern, not autosomal recessive.The autosomal dominant form is caused by mutations in the STAT3 (signal transducer and activator of transcription 3) gene, which plays a critical role in cytokine signaling, Th17 cell differentiation, and host defense. **Pathophysiology:** Defective STAT3 signaling → impaired differentiation of Th17 helper T cells. Leads to defective neutrophil recruitment and poor inflammatory response to bacterial infections. Impaired immunity to Staphylococcus aureus and Candida albicans infections. Failure of normal tissue remodeling results in skeletal and dental abnormalities. **Clinical Features:** Recurrent “cold” staphylococcal abscesses (non-inflamed), Pneumatoceles following pneumonia, Candidiasis (Candida albicans is the 2nd most common pathogen), Facial features: prominent forehead, broad nasal bridge, deep-set eyes, fleshy nasal tip, facial asymmetry, Skeletal findings: delayed shedding of primary teeth, scoliosis, recurrent fractures, osteopenia, Immunologic findings: extremely high IgE, eosinophilia, normal IgG/IgA/IgM, Allergic symptoms are usually absent, despite high IgE levels. **Therapy:** Prophylactic antibiotics/antifungals, and immunoglobulin replacement for recurrent infections.
- (A) Cataract and a congenital heart defect
- (B) Hypotonia and a congenital heart defect
- (C) Cutis aplasia and a congenital heart defect
- (D) Hypocalcemia and a congenital heart defect
💡 Click to Reveal Answer & Nelson Rationale
DiGeorge syndrome (22q11.2 deletion syndrome) is the most common T-cell immunodeficiency disorder and results from microdeletion of chromosome 22q11.2, which affects the development of the third and fourth pharyngeal pouches during embryogenesis. **Pathophysiology:** Maldevelopment of the third and fourth pharyngeal pouches leads to hypoplasia or aplasia of the thymus and parathyroid glands. This results in: T-cell immunodeficiency → recurrent infections, Hypocalcemia (due to hypoparathyroidism) → neonatal or infantile seizures, Congenital heart defects, especially conotruncal anomalies (e.g., truncus arteriosus, interrupted aortic arch, Tetralogy of Fallot) **Characteristic findings:** Hypocalcemia (neonatal seizures), Congenital heart disease (conotruncal anomalies, VSD, right aortic arch), Facial dysmorphism: short philtrum, hypertelorism, antimongoloid slant, mandibular hypoplasia, posteriorly rotated ears, Cleft palate or bifid uvula, Recurrent infections due to T-cell deficiency **The triad of DiGeorge syndrome:** Cardiac defects, Hypocalcemia, Immunodeficiency (T-cell defect). Hence, hypocalcemia with congenital heart defect is most diagnostic of DiGeorge syndrome.
- (A) B-cell defects
- (B) Complement defects
- (C) T-cell defects
- (D) Neutrophil defects
💡 Click to Reveal Answer & Nelson Rationale
T-cell immunodeficiencies lead to impaired cell-mediated immunity, resulting in susceptibility to opportunistic infections, failure to thrive, and malabsorption due to mucosal immune dysfunction. **Key clinical clues:** Failure to thrive due to chronic infection and poor nutrient absorption. Chronic diarrhea and malabsorption due to enteric infections or villous atrophy from immune dysfunction. Opportunistic infections such as: Candida species (mucocutaneous or systemic), Pneumocystis jiroveci (carinii) pneumonia, Viral infections (CMV, EBV, adenovirus), Mycobacterial infections in severe cases **Underlying mechanism:** T cells are critical for defense against intracellular organisms and fungi. Their deficiency leads to impaired macrophage activation and B-cell help, resulting in both cellular and humoral immune defects. **Common T-cell disorders include:** Severe combined immunodeficiency (SCID) – absent or dysfunctional T and B cells, DiGeorge syndrome (22q11.2 deletion) – thymic aplasia/hypoplasia, HIV infection – acquired T-cell dysfunction
- (A) Common variable immunodeficiency
- (B) Selective IgA deficiency
- (C) Bruton agammaglobulinemia
- (D) Hyper IgM syndrome
💡 Click to Reveal Answer & Nelson Rationale
An isolated absence or near absence (<5 mg/dL) of serum and secretory IgA is the most common well-defined immunodeficiency disorder, with a disease frequency as high as 0.33% in some populations. Patients may be asymptomatic or may develop sinopulmonary or gastrointestinal (GI) infections (especially Giardia). IgA deficiency is also associated with celiac disease and other autoimmune disorders. The diagnosis cannot be made until about 4 years of age, when IgA levels should be matured to adult levels.
- (A) Cardiac anomalies
- (B) Abnormal facies
- (C) Thymic hypoplasia
- (D) Cleft lip
💡 Click to Reveal Answer & Nelson Rationale
CATCH 22 syndrome (Cardiac anomalies, Abnormal facies, Thymic hypoplasia, Cleft palate, and Hypocalcemia) results from dysmorphogenesis of the third and fourth pharyngeal pouches, leading to hypoplasia of the thymus and parathyroid glands. The thymic defect impairs T-cell maturation, resulting in cellular immunodeficiency. Most patients have a chromosomal deletion at 22q11.2, hence the term “CATCH 22.” **Key features include:** Cardiac defects: Conotruncal anomalies (e.g., tetralogy of Fallot, interrupted aortic arch). Facial anomalies: Low-set ears, small mandible, short philtrum, Thymic hypoplasia: Recurrent viral and fungal infections due to T-cell deficiency, Cleft palate: Velopharyngeal insufficiency and nasal speech, Hypocalcemia: Due to parathyroid hypoplasia, leading to tetany or seizures Diagnosis is confirmed by fluorescent in situ hybridization (FISH) or PCR demonstrating a deletion on chromosome 22q11.2.
- (A) 2 years of age
- (B) 4 years of age
- (C) 6 years of age
- (D) 8 years of age
💡 Click to Reveal Answer & Nelson Rationale
An isolated absence or near absence (<5 mg/dL) of serum and secretory IgA is the most common well-defined immunodeficiency disorder, with a disease frequency as high as 0.33% in some populations. Patients may be asymptomatic or may develop sinopulmonary or gastrointestinal (GI) infections (especially Giardia). IgA deficiency is also associated with celiac disease and other autoimmune disorders. The diagnosis cannot be made until about 4 years of age, when IgA levels should be matured to adult levels.
- (A) AEC >1,500 cells/μL persisting for 4 months or longer or at least on two occasions or with evidence of tissue eosinophilia
- (B) Absence of another diagnosis to explain the eosinophilia
- (C) Signs and symptoms of organ involvement
- (D) AEC >1,500 cells/μL persisting for 6 months or longer or at least on two occasions or with evidence of tissue eosinophilia
💡 Click to Reveal Answer & Nelson Rationale
Hypereosinophilic syndrome (HES) represents a group of disorders characterized by persistent eosinophilia associated with end-organ damage. The three diagnostic criteria are: Absolute eosinophil count (AEC) >1,500 cells/μL, persisting for 6 months or longer, or documented on two occasions or with evidence of tissue eosinophilia. Absence of another identifiable cause for the eosinophilia (such as parasitic infection, allergy, or malignancy). Presence of signs and symptoms of organ involvement, such as those affecting the heart, lungs, skin, or nervous system. The duration criterion is essential to distinguish transient eosinophilia from chronic idiopathic HES. Hence, persistence for 6 months (and not 4 months) is diagnostic.
- (A) X-linked recessive
- (B) Autosomal dominant
- (C) Autosomal recessive
- (D) Mitochondrial
💡 Click to Reveal Answer & Nelson Rationale
Leukocyte Adhesion Deficiency (LAD) is a group of rare primary immunodeficiency disorders characterized by defective leukocyte adhesion and migration to sites of infection due to mutations affecting adhesion molecules on neutrophils. All three forms — LAD-1, LAD-2, and LAD-3 — exhibit autosomal recessive inheritance. ![[3c8db17b_Untitled_design__46__1762244693.png]]
- (A) Severe neutropenia
- (B) Marked leukocytosis with neutrophilia
- (C) Eosinophilia
- (D) Lymphopenia
💡 Click to Reveal Answer & Nelson Rationale
In Leukocyte Adhesion Deficiency type 1 (LAD-1), neutrophils are produced normally in the bone marrow but are unable to adhere to and migrate through the vascular endothelium to reach infected tissues due to absence of CD11/CD18 (β2-integrins) on leukocyte membranes. As a result, neutrophils remain trapped in the circulation, leading to persistent and marked leukocytosis with neutrophilia — often exceeding 50,000/mm³ — despite the presence of infection. **Key clinical features of LAD-1:** Delayed umbilical cord separation, Recurrent bacterial infections without pus formation, Poor wound healing, Absence of neutrophils at sites of infection despite high circulating counts
- (A) Severe neutropenia
- (B) Defective platelet aggregation with bleeding tendency
- (C) Hypocalcemia
- (D) Absent thymic shadow
💡 Click to Reveal Answer & Nelson Rationale
LAD type III is caused by mutations in the FERMT3 gene, which encodes Kindlin-3, a protein essential for activation of β-integrins in both leukocytes and platelets. Although integrins are structurally present, they cannot be activated, resulting in impaired leukocyte adhesion and defective platelet aggregation. **This leads to a unique combination of:** Recurrent bacterial infections (due to defective leukocyte adhesion and migration), Bleeding tendency resembling Glanzmann thrombasthenia (due to impaired platelet integrin activation and aggregation) ![[5784ce90_Untitled_design__47__1762245360.png]] The typical LAD triad includes delayed umbilical cord separation, absence of pus, and leukocytosis.
- (A) Autosomal dominant syndrome
- (B) Occurs due to defect in LYST gene on chromosome 1q2–q44
- (C) Associated with peripheral neuropathy
- (D) Have prolonged bleeding time with normal platelets
💡 Click to Reveal Answer & Nelson Rationale
Chediak–Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by abnormalities in lysosomal trafficking, leading to defective formation and function of cytoplasmic granules in multiple cell types including leukocytes, melanocytes, and platelets. It is caused by mutations in the LYST gene (lysosomal trafficking regulator) located on chromosome 1q2–q44. **Key features include: **Defective neutrophil degranulation → recurrent bacterial and fungal infections (commonly Staphylococcus aureus), Partial oculocutaneous albinism → light skin, silvery hair, photophobia, nystagmus, Mild bleeding diathesis → prolonged bleeding time with normal platelet count (due to defective dense granule formation), Progressive peripheral neuropathy and cranial nerve dysfunction, Hemophagocytic lymphohistiocytosis (accelerated phase) → life-threatening condition with fever, hepatosplenomegaly, cytopenias
- (A) BTK gene
- (B) LYST gene
- (C) WASP gene
- (D) CYBB gene
💡 Click to Reveal Answer & Nelson Rationale
Chediak–Higashi syndrome (CHS) is caused by autosomal recessive mutations in the LYST (lysosomal trafficking regulator) gene, which plays a critical role in regulating vesicle trafficking and fusion within cells. The LYST gene is located on chromosome 1q2–q44, and its product — the LYST/CHS protein — mediates protein–protein and protein–membrane interactions required for normal lysosomal transport. Loss of function of this gene leads to abnormal fusion of lysosomes, resulting in the formation of giant granules in leukocytes, melanocytes, and platelets. This impairs neutrophil degranulation, melanin distribution, and platelet aggregation. **Nelson states:** “LYST (for lysosomal traffic regulator), the gene variant in CHS, is located at chromosome 1q2–q44. The LYST/CHS protein is thought to regulate vesicle transport by mediating protein–protein interaction and protein–membrane associations. Loss of function may lead to indiscriminate interactions with lysosomal surface proteins, yielding giant granules through uncontrolled fusion of lysosomes with each other.”
- (A) Autosomal dominant immune deficiency
- (B) Increased susceptibility to Staphylococcus aureus infections
- (C) Often detected incidentally on neutrophil function testing
- (D) Presents early in infancy with severe pyogenic infections
💡 Click to Reveal Answer & Nelson Rationale
Myeloperoxidase (MPO) deficiency is a relatively common inherited disorder of neutrophil function caused by mutations in the MPO gene, leading to absent or reduced MPO enzyme activity in neutrophils and monocytes. MPO catalyzes the conversion of hydrogen peroxide and chloride ions into hypochlorous acid (HOCl), a potent antimicrobial agent. Despite this defect, most individuals remain asymptomatic because other oxidative killing mechanisms compensate adequately. The condition is therefore usually detected incidentally during neutrophil oxidative burst testing (e.g., nitroblue tetrazolium or dihydrorhodamine assays). In rare cases, symptomatic patients—especially those with diabetes mellitus—may have increased susceptibility to Candida infections, not Staphylococcus aureus.
- (A) VOD typically presents months to years after transplant with isolated cough
- (B) VOD presents early (within ~30 days) with hepatomegaly, right-upper-quadrant pain, rapid weight gain/ascites, hyperbilirubinemia; severity grading uses bilirubin, renal function, weight gain/ascites, and respiratory compromise
- (C) VOD is prevented by routine high-dose aspirin
- (D) VOD diagnosis requires liver biopsy in every case
💡 Click to Reveal Answer & Nelson Rationale
Veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT) caused by toxic endothelial injury within the hepatic sinusoids due to conditioning regimens. **It typically presents within the first month (≤30 days) post-transplant with:** Tender hepatomegaly, Right upper quadrant pain, Jaundice / rising bilirubin, Rapid weight gain and ascites from fluid retention, Possible renal and respiratory compromise in severe cases Severity grading is based on bilirubin levels, renal dysfunction, weight gain/ascites, and respiratory support requirement, as described in Nelson’s Table 179.3. **Treatment:** Supportive care (fluid restriction, diuretics, avoidance of hepatotoxins), Defibrotide is the only proven therapy for severe VOD and may also be used for prophylaxis in high-risk patients.
- (A) Any transient neutropenia within 7 days post-transplant
- (B) Failure to achieve an absolute neutrophil count (ANC) ≥0.5 ×10⁹/L by a specified post-transplant time (commonly by day +28) with evidence of donor engraftment failure
- (C) Immediate post-transplant diarrhea only
- (D) Elevated bilirubin >15 mg/dL only
💡 Click to Reveal Answer & Nelson Rationale
Primary graft failure is a serious complication of allogeneic HSCT defined as the failure to achieve sustained neutrophil recovery to an absolute neutrophil count (ANC) ≥0.5 ×10⁹/L within the expected time frame—commonly assessed by day +28 post-transplant. This condition indicates lack of donor engraftment, which is confirmed by bone marrow examination and donor chimerism studies showing absence of donor-derived hematopoiesis. **Etiology and Risk Factors:** HLA mismatch or graft rejection, Low stem cell dose, Severe infections, Prior irradiation or chemotherapy, ABO or minor antigen incompatibility **Consequences:** Persistent aplasia with severe neutropenia, Life-threatening infections and bleeding, High mortality without re-transplantation **Management:** Evaluate for reversible causes (infection, drug toxicity, immune-mediated rejection), Second HSCT or donor stem cell boost may be required, Intensive supportive care (antibiotics, transfusions, growth factors)
- (A) The highest risk for invasive fungal disease (aspergillosis) is only after day +100
- (B) Early (preengraftment, ≈ first 30 days) risk is dominated by neutropenia-associated bacterial and Candida infections; intermediate (30–100 days) risk includes CMV, opportunistic viruses, and invasive molds; late (>100 days) risk reflects chronic GVHD and encapsulated organisms.
- (C) Viral reactivations (e.g., CMV) occur exclusively in the first week post-transplant
- (D) Bacterial infections are rare throughout all phases if a central line is present
💡 Click to Reveal Answer & Nelson Rationale
After allogeneic hematopoietic stem cell transplantation (HSCT), infection risk follows three immunologic phases, each defined by characteristic host immune defects and pathogen patterns. This staged model guides prophylaxis and diagnostic vigilance in HSCT patients.
- (A) EBV-PTLD occurs exclusively >5 years after transplant and is not associated with T-cell depletion.
- (B) Early EBV-PTLD often presents in the first 1–6 months post-transplant, especially after T-cell depletion or antilymphocyte therapy; first-line therapy for high-risk or confirmed disease includes reduction of immunosuppression and rituximab (anti-CD20) for B-cell PTLD.
- (C) PTLD is treated best with prolonged high-dose antibiotics.
- (D) EBV viral load monitoring is not useful for early detection.
💡 Click to Reveal Answer & Nelson Rationale
According to Nelson, Epstein-Barr virus–associated post-transplant lymphoproliferative disease (EBV-PTLD) typically occurs early (within 1–6 months) following hematopoietic stem cell transplantation (HSCT), particularly when T-cell immunity is impaired, such as after T-cell depletion or antithymocyte globulin (ATG) use. Clinical presentation:Ranges from fever and lymphadenopathy to fulminant B-cell proliferation involving extranodal sites like the liver, lungs, or gastrointestinal tract. **Diagnosis and Management:** EBV viral load monitoring (PCR-based) is crucial for early detection in high-risk patients. First-line therapy involves: Reduction of immunosuppression (if feasible), Rituximab (anti-CD20 monoclonal antibody) for B-cell PTLD, Refractory or relapsed cases may require chemotherapy or EBV-specific cytotoxic T-cell therapy.
- (A) Agammaglobulinemia
- (B) Common variable immunodeficiency
- (C) Transient hypogammaglobulinemia of infancy
- (D) IgA deficiency
💡 Click to Reveal Answer & Nelson Rationale
Agammaglobulinemia (X-linked, Bruton’s agammaglobulinemia) is caused by a mutation in the BTK (Bruton’s tyrosine kinase) gene, leading to arrest of B-cell maturation at the pre–B-cell stage. **Key features:** Atrophied tonsils and lymph nodes due to absence of mature B cells, Recurrent bacterial infections (e.g., pneumonia, otitis, meningitis) after 6 months of age, when maternal IgG levels wane, Markedly low or absent immunoglobulins (IgG, IgA, IgM), Normal T-cell numbers and function. This child’s recurrent pneumonias beginning after 6 months, absent tonsils, and bacterial infections are classic for X-linked agammaglobulinemia.
- (A) Ataxia-telangiectasia
- (B) Wiskott–Aldrich syndrome
- (C) Severe combined immunodeficiency (SCID)
- (D) Hyper-IgE (Job’s) syndrome
💡 Click to Reveal Answer & Nelson Rationale
Wiskott–Aldrich Syndrome (WAS) is a classic X-linked recessive primary immunodeficiency characterized by the triad of: Eczema (atopic dermatitis), Recurrent infections (bacterial, viral, fungal), Thrombocytopenia with small platelets (↓ MPV) ![[e8fc09c3_Untitled_design__49__1762248409.png]] **Clinical consequences:** Patients present with recurrent infections, bleeding tendencies, eczema, and increased risk of EBV-associated lymphomas. **Mnemonic:** WATER W – Wiskott–Aldrich, A – Atopic dermatitis (eczema), T – Thrombocytopenia (small platelets), E – Elevated IgE and IgA, R – Recurrent infections
- (A) Transient hypogammaglobulinemia of infancy
- (B) X-linked agammaglobulinemia
- (C) Hyper IgM syndrome
- (D) Selective IgA deficiency
💡 Click to Reveal Answer & Nelson Rationale
X-linked (Bruton) agammaglobulinemia (XLA) is caused by mutations in the BTK (Bruton tyrosine kinase) gene, resulting in an arrest of B-cell maturation at the pre–B-cell stage. This leads to an absence of mature B cells (CD19⁺) and markedly decreased levels of all immunoglobulin classes (IgG, IgA, IgM). **Characteristic features:** Age of onset: After 6 months (when maternal antibodies wane), Clinical findings: Recurrent pyogenic infections—otitis media, pneumonia, sinusitis, diarrhea, Physical findings: Absent tonsils and lymph nodes (due to lack of mature B cells), Laboratory findings: Absent B cells on flow cytometry (CD19⁺ negative), normal T-cell count, all Ig levels low or absent **Genetic basis:** BTK gene mutation (X chromosome) → failure of B-cell development → no plasma cells → no antibody production, Inheritance: X-linked recessive → affects males
- (A) Class switch recombination
- (B) Somatic hypermutation
- (C) Antigen presentation via MHC II
- (D) VDJ recombination
💡 Click to Reveal Answer & Nelson Rationale
X-linked Hyper IgM syndrome (CD40L deficiency) is caused by mutations in the CD40 ligand (CD40L/CD154) gene on activated CD4⁺ T cells. The CD40L–CD40 interaction between T cells and B cells is required for class switch recombination (CSR) and somatic hypermutation. When CD40L is absent, B cells cannot switch immunoglobulin isotypes from IgM to IgG, IgA, or IgE, resulting in: Markedly elevated IgM levels Low or absent IgG, IgA, and IgE **Nelson states:**“The hyper-IgM syndrome is genetically heterogeneous and characterized by normal or elevated serum IgM levels associated with low or absent IgG, IgA, and IgE levels, indicating a defect in the class switch recombination process.” **Clinical features:** Recurrent pyogenic and opportunistic infections (especially Pneumocystis jirovecii), Neutropenia, chronic diarrhea, and autoimmune manifestations, X-linked inheritance, affecting males
- (A) It is usually associated with absent B cells and low IgG levels.
- (B) Live vaccines are contraindicated due to risk of severe infection.
- (C) The patient is at risk of anaphylaxis if transfused with plasma-containing blood products.
- (D) It progresses to X-linked agammaglobulinemia in adulthood.
💡 Click to Reveal Answer & Nelson Rationale
Selective IgA Deficiency (SIgAD) is the most common primary immunodeficiency, with a prevalence of approximately 1:600 in Caucasians. Definition:Serum IgA <7 mg/dL with normal IgG and IgM levels in a patient >4 years old with otherwise normal immune function. Mechanism:Defective terminal differentiation of B cells into IgA-secreting plasma cells. T-cell function and other immunoglobulin classes remain normal. **Clinical features:** Often asymptomatic, Recurrent sinopulmonary infections (Streptococcus pneumoniae, H. influenzae), Giardia lamblia infection due to mucosal IgA deficiency, Increased risk of autoimmune diseases (celiac disease, SLE, rheumatoid arthritis), Anaphylaxis after blood transfusion due to anti-IgA (IgE type) antibodies reacting to donor IgA in plasma
- (A) Class switch recombination
- (B) Somatic hypermutation
- (C) Antigen presentation via MHC II
- (D) VDJ recombination
💡 Click to Reveal Answer & Nelson Rationale
X-linked Hyper IgM syndrome (CD40L deficiency) is caused by mutations in the CD40 ligand (CD40L/CD154) gene on activated CD4⁺ T cells. The CD40L–CD40 interaction between T cells and B cells is required for class switch recombination (CSR) and somatic hypermutation. When CD40L is absent, B cells cannot switch immunoglobulin isotypes from IgM to IgG, IgA, or IgE, resulting in: Markedly elevated IgM levels Low or absent IgG, IgA, and IgE **Nelson states:**“The hyper-IgM syndrome is genetically heterogeneous and characterized by normal or elevated serum IgM levels associated with low or absent IgG, IgA, and IgE levels, indicating a defect in the class switch recombination process.” **Clinical features:** Recurrent pyogenic and opportunistic infections (especially Pneumocystis jirovecii), Neutropenia, chronic diarrhea, and autoimmune manifestations, X-linked inheritance, affecting males
- (A) Defect in NADPH oxidase → defective intracellular killing
- (B) Deficiency of integrins → impaired leukocyte adhesion and migration
- (C) Defective fusion of phagosome with lysosome
- (D) Defective microtubule assembly → impaired chemotaxis
💡 Click to Reveal Answer & Nelson Rationale
Leukocyte Adhesion Deficiency type 1 (LAD-1) is an autosomal recessive disorder caused by mutations in the ITGB2 gene, which encodes the β₂ integrin (CD18) molecule on neutrophils. **Pathophysiology:** Absence of CD18 leads to defective expression of leukocyte adhesion molecules (β₂ integrins: CD11a/CD18, CD11b/CD18). This prevents neutrophil adhesion to vascular endothelium and migration into infected tissues. As a result, patients develop recurrent bacterial infections without pus, delayed wound healing, delayed umbilical cord separation, and marked leukocytosis due to trapped neutrophils in circulation. Normal NBT test distinguishes LAD-1 from Chronic Granulomatous Disease (CGD).
- (A) Chronic granulomatous disease
- (B) Congenital leukemia
- (C) Kostmann syndrome
- (D) Leukocyte adhesion deficiency (LAD)
💡 Click to Reveal Answer & Nelson Rationale
Leukocyte Adhesion Deficiency (LAD) is an autosomal recessive immunodeficiency caused by absence or defect of CD18 (β₂-integrin), required for neutrophil adhesion and migration through endothelium. **Key diagnostic features in this case:** Persistent umbilical cord beyond 3 weeks → Delayed cord separation, Marked leukocytosis with neutrophilia (WBC >50,000/mm³), Recurrent bacterial infections without pus formation, Severe sepsis in early infancy, Positive family history suggesting a genetic defect. These features are diagnostic of LAD type 1, due to mutations in the ITGB2 gene, leading to defective β₂-integrin (CD18) expression. **Confirmatory test:** Flow cytometry: Absent CD18 expression on neutrophils. Inheritance:Autosomal recessive
- (A) Long-term prophylactic antibiotics and IVIG will cure the underlying defect and prevent the accelerated phase.
- (B) Allogeneic hematopoietic stem-cell transplantation (HSCT) performed early can correct the immune/hematologic defects and reduce mortality, but neurologic degeneration may persist.
- (C) HSCT is contraindicated because CHS is purely a pigmentary disorder and not amenable to transplant.
- (D) Bone marrow findings and ferritin indicate iron overload; iron chelation is the mainstay of therapy.
💡 Click to Reveal Answer & Nelson Rationale
Chediak–Higashi syndrome (CHS) is an autosomal recessive disorder caused by mutations in the LYST gene, which encodes a lysosomal trafficking regulator protein. This leads to defective lysosomal fusion and formation of giant azurophilic granules in neutrophils, lymphocytes, and other cells. **Clinical features:** Partial oculocutaneous albinism (hypopigmented hair, skin, eyes), Recurrent pyogenic infections due to neutrophil dysfunction, Bleeding tendency from platelet dense-body defects, Progressive peripheral neuropathy, Accelerated phase (HLH-like) — characterized by fever, pancytopenia, hepatosplenomegaly, hyperferritinemia, and hemophagocytosis — a major cause of death **Prognosis and management:** Supportive therapy (antibiotics, IVIG) can manage infections but does not prevent or correct the underlying cytotoxic defect or accelerated phase. Allogeneic HSCT replaces defective hematopoietic cells, thereby correcting immune and hematologic dysfunction, reducing infection risk, and preventing or treating the accelerated HLH-like phase if performed early. However, neurological degeneration (ataxia, neuropathy, cognitive decline) is due to LYST dysfunction in neurons and does not fully improve post-transplant. HSCT remains the only curative therapy for the hematologic and immune manifestations.
- (A) All live bacterial and viral vaccines are absolutely contraindicated in CGD.
- (B) BCG vaccine should be avoided in CGD infants in countries where it is optional, but MMR and varicella are generally given per schedule with caution.
- (C) All live vaccines are required because CGD causes combined B- and T-cell failure.
- (D) Live vaccines should be given only after IFN-γ therapy is started.
💡 Click to Reveal Answer & Nelson Rationale
Chronic Granulomatous Disease (CGD) is a phagocytic disorder caused by a defect in the NADPH oxidase enzyme complex, leading to failure of intracellular killing of catalase-positive organisms such as Staphylococcus aureus, Serratia marcescens, Burkholderia cepacia, and Aspergillus species. Adaptive immunity (B and T cells) remains intact in CGD, so most viral vaccines are safe. BCG vaccine (live attenuated Mycobacterium bovis) poses a significant risk of disseminated infection due to defective macrophage killing and is avoided in CGD infants in regions where BCG is optional. Live viral vaccines such as MMR and varicella are generally considered safe and administered as per routine schedule, unless the patient is acutely ill or undergoing HSCT evaluation. Therefore, the BCG vaccine is the primary concern, not all live vaccines. Consultation with an immunologist and adherence to local vaccine policy are essential for individualized management.
- (A) This is bronchiolitis obliterans as a manifestation of chronic GVHD; management includes treating underlying cGVHD (systemic immunosuppression, inhaled steroids/bronchodilators, macrolides, and consider ECP/rituximab/ibrutinib or pulmonary referral for rehabilitation).
- (B) This is primary pulmonary TB – give 6-month anti-TB therapy immediately.
- (C) Discontinue all immunosuppression to allow infection clearance.
- (D) Bronchiolitis obliterans is self-limited and requires no therapy.
💡 Click to Reveal Answer & Nelson Rationale
Bronchiolitis obliterans (BO) is a recognized pulmonary manifestation of chronic graft-versus-host disease (cGVHD) following allogeneic HSCT. It occurs due to immune-mediated inflammatory injury of the small airways, leading to fibrotic narrowing and airflow obstruction. The coexistence of sicca symptoms (xerophthalmia) and scleroderma-like skin changes strongly supports the diagnosis of cGVHD-associated BO. Management focuses on treating the underlying cGVHD and preventing further pulmonary deterioration. This involves systemic immunosuppression using corticosteroids as first-line therapy, with the addition of steroid-sparing agents such as ibrutinib or ruxolitinib in refractory cases. Inhaled corticosteroids, bronchodilators, and macrolides (e.g., azithromycin) are used for their anti-inflammatory benefits. Extracorporeal photopheresis (ECP) or rituximab can be considered in resistant disease. Supportive strategies include pulmonary rehabilitation, vaccination, and avoidance of respiratory irritants. Early recognition and prompt therapy can stabilize or improve lung function and reduce mortality.
- (A) Start IV vancomycin + amphotericin B
- (B) Start oral ciprofloxacin + discharge on OPD follow-up
- (C) Start IV piperacillin-tazobactam immediately
- (D) Wait for cultures before starting antibiotics
💡 Click to Reveal Answer & Nelson Rationale
In a post-HSCT patient with febrile neutropenia (ANC <500/μL), this represents a medical emergency. The child is considered high risk due to profound neutropenia, presence of a central line, and recent transplant. The most appropriate immediate step is to initiate empiric broad-spectrum intravenous antibiotics covering Pseudomonas aeruginosa and other gram-negative bacilli. Piperacillin-tazobactam is a first-line antipseudomonal β-lactam recommended by Nelson (Table 180.1) and major HSCT infection protocols. Empiric therapy should not be delayed for culture results, as delays in neutropenic fever management significantly increase mortality. Once cultures and sensitivities return, therapy can be adjusted accordingly. **Additional management steps include:** Obtain two sets of blood cultures (from central and peripheral lines) before antibiotics, if feasible without delay. Monitor vitals, blood counts, and renal function. Add vancomycin only if there are signs of catheter-related infection, MRSA risk, hypotension, or severe mucositis. Add antifungal therapy (e.g., amphotericin B or echinocandin) only if fever persists beyond 4–7 days despite broad-spectrum antibiotics or fungal infection is suspected.
- (A) TB treatment failure
- (B) ATT-induced hepatitis
- (C) IRIS due to immune reconstitution
- (D) PTLD
💡 Click to Reveal Answer & Nelson Rationale
Immune Reconstitution Inflammatory Syndrome (IRIS) represents a paradoxical inflammatory reaction that occurs when the recovering immune system mounts an exaggerated response to residual microbial antigens after a period of immunosuppression. In this HSCT recipient, improving blood counts indicate immune recovery during engraftment. The presence of new inflammatory lymphadenopathy, fever, negative cultures, and low TB PCR levels suggests inflammation rather than ongoing infection—typical for IRIS. The pathophysiology involves restoration of pathogen-specific T-cell responses, leading to hyperinflammatory cytokine release and tissue inflammation at sites of prior infection. **Management:** Continue the existing ATT regimen (no indication of treatment failure). Corticosteroids may be added if symptoms are severe to suppress the exaggerated immune response. Supportive care with close monitoring of inflammatory markers and organ function. Recognition of IRIS is crucial because misdiagnosis as treatment failure may lead to unnecessary changes in antimicrobial therapy.
- (A) CH50 level
- (B) ANA
- (C) HIV ELISA
- (D) Serum electrophoresis
💡 Click to Reveal Answer & Nelson Rationale
Recurrent Neisseria meningitidis infections in a child with normal immunoglobulin levels, normal lymphocyte subsets, and normal neutrophil oxidative burst (normal NBT test) strongly suggest a defect in the terminal complement pathway (C5–C9 components). The CH50 assay (total hemolytic complement test) evaluates the functional integrity of the classical complement pathway, including the terminal components (C5–C9) responsible for formation of the membrane attack complex (MAC). A markedly low or absent CH50 indicates deficiency of one or more terminal complement components. Patients with terminal complement deficiency are otherwise immunocompetent, but have a 10,000-fold increased risk of recurrent or disseminated Neisseria infections, particularly Neisseria meningitidis and N. gonorrhoeae. Diagnosis guides prophylactic vaccination (meningococcal conjugate + serogroup B vaccine) and antibiotic prophylaxis.
- (A) C1q
- (B) C5
- (C) Factor D
- (D) C9
💡 Click to Reveal Answer & Nelson Rationale
C1q deficiency is the strongest complement-related risk factor for developing systemic lupus erythematosus (SLE)-like disease. Early classical pathway components—C1q, C2, and C4—are crucial for the clearance of immune complexes and apoptotic debris. Their deficiency impairs this process, leading to persistent immune complex deposition and autoantibody production, hallmarks of SLE pathogenesis. Children with C1q, C2, or C4 deficiency often present with malar rash, photosensitivity, and positive ANA, closely resembling idiopathic SLE. Among these, C1q deficiency carries the highest penetrance (>90%) for lupus-like disease. In contrast, deficiencies of the terminal complement components (C5–C9) predispose primarily to recurrent Neisseria infections rather than autoimmunity.
- (A) Hereditary angioedema Type I
- (B) Allergic angioedema
- (C) ACE-inhibitor–induced angioedema
- (D) C3 deficiency
💡 Click to Reveal Answer & Nelson Rationale
Hereditary angioedema (HAE) Type I is an autosomal dominant disorder caused by quantitative deficiency of C1 esterase inhibitor (C1-INH). The resultant uncontrolled activation of the complement and kallikrein-kinin systems leads to excessive bradykinin production, causing recurrent, non-pruritic angioedema involving the face, extremities, larynx, or gastrointestinal tract. The diagnostic hallmark is low serum C4 along with decreased C1-INH antigenic level and function, as seen in this patient. Unlike allergic angioedema, urticaria and itching are absent, and episodes do not respond to antihistamines, epinephrine, or corticosteroids. Type I HAE accounts for approximately 85% of all HAE cases, characterized by low C1-INH level and function. Type II HAE, in contrast, shows normal or elevated C1-INH levels but decreased function due to dysfunctional protein. **Management:** Acute attacks: C1-INH concentrate, icatibant (bradykinin B2 receptor antagonist), or ecallantide (kallikrein inhibitor). Long-term prophylaxis: androgens (danazol), C1-INH prophylaxis, or lanadelumab in selected cases. Avoid triggers such as trauma, stress, or ACE inhibitors.